CVS Health is pulling from its shelves some cough-and-cold treatments that contain an ingredient that has been deemed ineffective by doctors and researchers.
The drug store chain said it will remove a small number of oral decongestants that contain phenylephrine as the only active ingredient. CVS also said it will still sell “many other oral cough and cold products to meet consumer needs.”
A company spokeswoman declined to elaborate on how many products will be removed when contacted by The Associated Press Friday morning.
CVS Health runs more than 9,000 stores in the United States. Representatives of its national rival, Walgreens, has not pulled any products.
A Walgreens spokeswoman said the company is monitoring the situation and partnering with its clinical integrity office and suppliers “on appropriate next steps.”
U.S. Food and Drug Administration advisers voted unanimously last month against the effectiveness of phenylephrine, which is found in popular versions of Sudafed, Dayquil and other medications stocked on store shelves.
The FDA had asked its outside advisers to examine the long-questioned drug ingredient. Studies conducted in the past few years by the drugmakers Merck and Johnson & Johnson have shown no difference between phenylephrine medications and placebos for relieving congestion.
The FDA, which has not acted on the recommendation of its advisers, said the drug appears more effective when applied directly to the nose, in sprays or drops. Those products are not under review.
Phenylephrine had become the main drug in over-the-counter decongestants when medicines with an older ingredient — pseudoephedrine — were moved behind pharmacy counters. A 2006 law had forced the move because pseudoephedrine can be illegally processed into methamphetamine.
Those original versions of Sudafed and other medicines remain available without a prescription.
The CVS Health announcement comes shortly before another cold-and-flu season starts in the United States as winter sets in. Last year, an unusually fast start to the season led to shortages of Children’s Tylenol and other medications customers can purchase over-the-counter, or without a prescription.
Wealthfront’s CFO Alan Iberman talks the $2.05B IPO and the major moment for robo banking as the company bets on AI, automation, and “self-driving money."
A rare magnum of Dom Pérignon Vintage 1961 champagne that was specially produced for the 1981 wedding of Prince Charles and Lady Diana has failed to sell during an auction. Danish auction house Bruun Rasmussen handled the bidding Thursday. The auction's house website lists the bottle as not sold. It was expected to fetch up to around $93,000. It is one of 12 bottles made to celebrate the royal wedding. Little was revealed about the seller. The auction house says the bids did not receive the desired minimum price.
The New York Times and President Donald Trump are fighting again. The news outlet said Wednesday it won't be deterred by Trump's “false and inflammatory language” from writing about the 79-year-old president's health. The Times has done a handful of stories on that topic recently, including an opinion column that said Trump is “starting to give President Joe Biden vibes.” In a Truth Social post, Trump said it might be treasonous for outlets like the Times to do “FAKE” reports about his health and "we should do something about it.” The Republican president already has a pending lawsuit against the newspaper for its past reports on his finances.
OpenAI has appointed Slack CEO Denise Dresser as its first chief of revenue. Dresser will oversee global revenue strategy and help businesses integrate AI into daily operations. OpenAI CEO Sam Altman recently emphasized improving ChatGPT, which now has over 800 million weekly users. Despite its success, OpenAI faces competition from companies like Google and concerns about profitability. The company earns money from premium ChatGPT subscriptions but hasn't ventured into advertising. Altman had recently announced delays in developing new products like AI agents and a personal assistant.
President Donald Trump says he will allow Nvidia to sell its H200 computer chip used in the development of artificial intelligence to “approved customers” in China. Trump said Monday on his social media site that he had informed China’s leader Xi Jinping and “President Xi responded positively!” There had been concerns about allowing advanced computer chips into China as it could help them to compete against the U.S. in building out AI capabilities. But there has also been a desire to develop the AI ecosystem with American companies such as chipmaker Nvidia.
